Alopecia Areata and Dexamethasone Mini-Pulse Therapy, A Prospective Cohort: Real World Evidence and Factors Related to Successful Response
Metadatos
Mostrar el registro completo del ítemAutor
Sánchez Díaz, Manuel; Montero Vílchez, Trinidad; Bueno Rodríguez, Ahinoa; Molina Leyva, Alejandro; Arias Santiago, Salvador AntonioEditorial
MDPI
Materia
Alopecia areata Mini-pulse therapy Corticosteroids Dexamethasone
Fecha
2022-03-18Referencia bibliográfica
Sánchez-Díaz, M... [et al.]. Alopecia Areata and Dexamethasone Mini-Pulse Therapy, a Prospective Cohort: RealWorld Evidence and Factors Related to Successful Response. J. Clin. Med. 2022, 11, 1694. [https://doi.org/10.3390/jcm11061694]
Resumen
The mini-pulse oral corticosteroids treatment for alopecia areata (AA) is an accessible
treatment whose efficacy and adverse effects have not yet been properly described. The objective of
the study was to assess the effectiveness and safety of the mini-pulse oral corticosteroids treatment
in patients with AA, and to explore potential factors associated to the response in a real-world
setting. An observational study of a prospective cohort to assess the effectiveness and safety of
a mini-pulse dexamethasone treatment in patients with AA, who failed to improve with topical
therapies, was performed. A SALT II score and other clinical and safety variables were recorded
at baseline, 3, 6, 9, and 12 months. An overall significant and progressive decrease of the SALT
score was found during treatment: SALT-50 response was achieved after 9 months in 51.8% of
the patients. Hypothyroidism and early age of onset were predictors of the lack of response to
treatment. The treatment combination with oral minoxidil showed no effect on the SALT score
reduction. Dexamethasone daily and cumulative dose were associated with a higher percentage of
side effects. To conclude, the mini-pulse oral corticosteroids treatment is an effective treatment for
AA, although patients with an early onset of the disease and hypothyroidism may not benefit.